Phase 2 study of cabozantinib (cabo) and pembrolizumab (pembro) in metastatic gastric/gastroesophageal adenocarcinoma (mGEA) refractory to immune checkpoint inhibitors (ICIs).
Dr. Sachin Ambekar, Director – Minimal Access and Bariatric Surgery, MASSH New Delhi, January 27, 2026: While laparoscopic procedures are widely performed across ...
Clinical significance of obesity index (VFA versus BMI) as a risk factor for gastric cancer surgery. Retrospective cohort study on the risk factors of admission due to serious adverse events during ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results